FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043249924> ?p ?o ?g. }

• W3043249924 endingPage "10269" @default.
• W3043249924 startingPage "10267" @default.
• W3043249924 abstract "Dear Editor, Since its first identification as a human pathogen in the Wuhan province of China in December 2019, the SARS-CoV-2 virus, which causes COVID-19, has become a global pandemic with immense medical and socio-economic costs. Like other coronaviruses, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 is a single-stranded positive-sense RNA virus. The SARS-COV-2 as well as the SARS-COV and MERS-COV genomes contain several open-reading frames (ORFs) that play an essential role in viral pathogenicity and infection.1-3 Based on previous experiences with other coronaviruses, ORFs are considered to be essential for viral replication through encoding viral replicase proteins to synthesize mRNAs of subgenomic length.1, 3 Silencing or small/short interfering RNA (siRNA) is a gene silencing approach using a small fragment of approximately 20-25 base pairs of double-stranded RNA that binds to a specific site of the relevant/target messenger RNA (mRNA); siRNAs are designed to silence genes at the post-transcriptional level (by inducing cleavage and subsequent degradation of target mRNA) and can therefore be considered as vaccines or therapeutic agents. Zheng et al4 designed 48 siRNA sequences that potentially target the entire SARS-CoV genome RNA, including ORFs for the translation of several key proteins. Among these, four siRNAs that could inhibit SARS-CoV infection in foetal rhesus monkey kidney cells (FRhK-4), both in a prophylactic and post-infection therapeutic manner, were identified. Translating this idea to live animal experiments, Li et al5 demonstrated a similar efficacy of siRNAs in a rhesus macaque (Macaca mulatta) SARS model. These agents, with no visible signs of toxicity, were shown to improve several symptoms of SARS-CoV, such as fever, viral load and acute alveolar damage. Importantly, the efficacy of the siRNAs was evident at relatively small respiratory doses (10-40 mg/kg). Similar experiments have been performed with different siRNA sequences targeting various regions of the SARS-CoV genome. For example, He et al6 showed that miRNAs targeting the replicase 1A region were more effective against the virus in FRhK-4 cells. In 293 and HeLa cells, siRNAs targeting SARS-CoV RNA-dependent RNA polymerase (RDRP) showed therapeutic potential as well by specifically inhibiting RDRP expression.7 In addition, this system reduced plaque formation in Vero-E6 cells, a cell line classically used to identify and count hemorrhagic fever viruses. In these cells, siRNA to target and inhibit gene expression of SARS-CoV spike (S) protein has been successfully utilized in vitro.8, 9 Similarly, siRNAs efficiently targeting S protein coding regions have been identified using FRhk-4 cells and an in vivo rhesus macaque model of SARS-CoV infection.10 In line with these findings, the aforementioned efficacy of the siRNA developed by Li et al5 was based on the S protein coding and ORF1b (NSP12) regions. Envelope (E) and membrane (M) proteins could also be (specifically) targeted, as demonstrated in SARS-CoV-infected FRhk-4 cells.11 In addition to synergistic effects that may be exhibited by different siRNAs, their therapeutic action can synergize with other currently existing antiviral agents through direct or indirect targeting common structural genes or other cellular targets.11, 12 In principle, several proteins encoded by the viral genome can be targeted by siRNA technology.13 He et al14 demonstrated the power of synergistic antiviral effects through siRNA targeting of various structural genes such as S, envelope, membrane and nucleocapsid. An additional advantage of siRNA technology is the incredibly low dose required to eliminate SARS-CoV infection; for example, less than 60 nmol/L in Vero E6 cells15 and 10-40 mg/kg/daily in monkeys was sufficient for satisfactory therapeutic effects.5 The application and potential effectiveness of siRNAs have also been evaluated in MERS-CoV using computational models.16 In view of angiotensin-converting enzyme 2 (ACE2) as a recognized host cell receptor for the SARS-CoV S protein, the development of siRNAs targeting key host proteins could hold promise. Indeed, silencing ACE2 expression in Vero E6 cells by siRNA (containing sequences homologous to a section of ACE2) significantly reduced SARS-CoV infection.17 Overall, the described studies on the effectiveness of specific siRNAs to battle SARS-CoV and MERS-CoV provide sufficient rationale to at least consider the use of siRNA strategies to target the closely related virus SARS-CoV-2. Despite their promising therapeutic effects, the application of higher doses of siRNAs, if so required, may be associated with some challenges, including adaptive18 and innate immune responses,19, 20 unwanted target effects, and saturation of the endogenous small RNA machinery.21 It is comforting, however, that previous data from several randomised, double-blind, placebo-controlled trials indicate that ALN-RSV01 (a siRNA-based drug) is safe to use and effective against respiratory syncytial virus infection.22, 23 Taken together, siRNA-based therapeutics might be considered as an effective strategy to treat of COVID-19. Future studies are warranted to evaluate their potential efficacy and safety. The authors declare no competing interests. Solomon Habtemariam: Formal analysis (equal); Investigation (equal). Ioana Berindan-Neagoe: Conceptualization (equal); Investigation (equal). Cosmin Andrei Cismaru: Formal analysis (equal); Methodology (equal). Dedmer Schaafsma: Investigation (equal); Methodology (equal). Seyed Fazel Nabavi: Conceptualization (equal); Data curation (equal). Saeid Ghavami: Investigation (equal); Methodology (equal). Maciej Banach: Investigation (equal); Methodology (equal). Seyed Mohammad Nabavi: Conceptualization (equal); Formal analysis (equal)." @default.
• W3043249924 created "2020-07-23" @default.
• W3043249924 creator A5020632057 @default.
• W3043249924 creator A5022534617 @default.
• W3043249924 creator A5031302075 @default.
• W3043249924 creator A5046431472 @default.
• W3043249924 creator A5050614530 @default.
• W3043249924 creator A5054475100 @default.
• W3043249924 creator A5059244618 @default.
• W3043249924 creator A5064654998 @default.
• W3043249924 date "2020-07-17" @default.
• W3043249924 modified "2023-10-01" @default.
• W3043249924 title "Lessons from SARS and MERS remind us of the possible therapeutic effects of implementing a siRNA strategy to target COVID‐19: Shoot the messenger!" @default.
• W3043249924 cites W1971643509 @default.
• W3043249924 cites W1977354935 @default.
• W3043249924 cites W1995420096 @default.
• W3043249924 cites W2006231275 @default.
• W3043249924 cites W2017003565 @default.
• W3043249924 cites W2019431237 @default.
• W3043249924 cites W2024312910 @default.
• W3043249924 cites W2032758490 @default.
• W3043249924 cites W2043828851 @default.
• W3043249924 cites W2060889706 @default.
• W3043249924 cites W2062563298 @default.
• W3043249924 cites W2066524276 @default.
• W3043249924 cites W2073858684 @default.
• W3043249924 cites W2079609256 @default.
• W3043249924 cites W2120820989 @default.
• W3043249924 cites W2148086787 @default.
• W3043249924 cites W2156732206 @default.
• W3043249924 cites W2255243349 @default.
• W3043249924 cites W2406013198 @default.
• W3043249924 cites W2415811952 @default.
• W3043249924 cites W2747597014 @default.
• W3043249924 cites W3016885766 @default.
• W3043249924 cites W4205209521 @default.
• W3043249924 doi "https://doi.org/10.1111/jcmm.15652" @default.
• W3043249924 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7405483" @default.
• W3043249924 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32677763" @default.
• W3043249924 hasPublicationYear "2020" @default.
• W3043249924 type Work @default.
• W3043249924 sameAs 3043249924 @default.
• W3043249924 citedByCount "7" @default.
• W3043249924 countsByYear W30432499242021 @default.
• W3043249924 countsByYear W30432499242022 @default.
• W3043249924 crossrefType "journal-article" @default.
• W3043249924 hasAuthorship W3043249924A5020632057 @default.
• W3043249924 hasAuthorship W3043249924A5022534617 @default.
• W3043249924 hasAuthorship W3043249924A5031302075 @default.
• W3043249924 hasAuthorship W3043249924A5046431472 @default.
• W3043249924 hasAuthorship W3043249924A5050614530 @default.
• W3043249924 hasAuthorship W3043249924A5054475100 @default.
• W3043249924 hasAuthorship W3043249924A5059244618 @default.
• W3043249924 hasAuthorship W3043249924A5064654998 @default.
• W3043249924 hasBestOaLocation W30432499241 @default.
• W3043249924 hasConcept C104317684 @default.
• W3043249924 hasConcept C119056186 @default.
• W3043249924 hasConcept C142724271 @default.
• W3043249924 hasConcept C159047783 @default.
• W3043249924 hasConcept C166703698 @default.
• W3043249924 hasConcept C167625842 @default.
• W3043249924 hasConcept C189819185 @default.
• W3043249924 hasConcept C2191507 @default.
• W3043249924 hasConcept C22615655 @default.
• W3043249924 hasConcept C2777648638 @default.
• W3043249924 hasConcept C2779134260 @default.
• W3043249924 hasConcept C2780530800 @default.
• W3043249924 hasConcept C3008058167 @default.
• W3043249924 hasConcept C41258723 @default.
• W3043249924 hasConcept C47289529 @default.
• W3043249924 hasConcept C524204448 @default.
• W3043249924 hasConcept C54355233 @default.
• W3043249924 hasConcept C67705224 @default.
• W3043249924 hasConcept C71924100 @default.
• W3043249924 hasConcept C86803240 @default.
• W3043249924 hasConceptScore W3043249924C104317684 @default.
• W3043249924 hasConceptScore W3043249924C119056186 @default.
• W3043249924 hasConceptScore W3043249924C142724271 @default.
• W3043249924 hasConceptScore W3043249924C159047783 @default.
• W3043249924 hasConceptScore W3043249924C166703698 @default.
• W3043249924 hasConceptScore W3043249924C167625842 @default.
• W3043249924 hasConceptScore W3043249924C189819185 @default.
• W3043249924 hasConceptScore W3043249924C2191507 @default.
• W3043249924 hasConceptScore W3043249924C22615655 @default.
• W3043249924 hasConceptScore W3043249924C2777648638 @default.
• W3043249924 hasConceptScore W3043249924C2779134260 @default.
• W3043249924 hasConceptScore W3043249924C2780530800 @default.
• W3043249924 hasConceptScore W3043249924C3008058167 @default.
• W3043249924 hasConceptScore W3043249924C41258723 @default.
• W3043249924 hasConceptScore W3043249924C47289529 @default.
• W3043249924 hasConceptScore W3043249924C524204448 @default.
• W3043249924 hasConceptScore W3043249924C54355233 @default.
• W3043249924 hasConceptScore W3043249924C67705224 @default.
• W3043249924 hasConceptScore W3043249924C71924100 @default.
• W3043249924 hasConceptScore W3043249924C86803240 @default.
• W3043249924 hasIssue "17" @default.
• W3043249924 hasLocation W30432499241 @default.
• W3043249924 hasLocation W30432499242 @default.

• next